67 related articles for article (PubMed ID: 18070286)
1. Biochemical and Structural Properties of Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations.
Nakajima S; Watashi K; Kato T; Muramatsu M; Wakita T; Tamura N; Hattori SI; Maeda K; Mitsuya H; Yasutake Y; Toyoda T
J Virol; 2021 Jul; 95(16):e0240120. PubMed ID: 34076480
[TBL] [Abstract][Full Text] [Related]
2. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.
Levine S; Hernandez D; Yamanaka G; Zhang S; Rose R; Weinheimer S; Colonno RJ
Antimicrob Agents Chemother; 2002 Aug; 46(8):2525-32. PubMed ID: 12121928
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus reverse transcriptase polymorphisms between treated and treatment-naïve chronically infected patients.
Rezanezhadi M; Mohebbi A; Askari FS; Hosseini SD; Tabarraei A
Virusdisease; 2019 Jun; 30(2):219-226. PubMed ID: 31179360
[TBL] [Abstract][Full Text] [Related]
4. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
Choi YM; Lee SY; Kim BJ
World J Gastroenterol; 2018 Apr; 24(16):1708-1724. PubMed ID: 29713126
[TBL] [Abstract][Full Text] [Related]
5. Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B.
Pacheco SR; Dos Santos MIMA; Stocker A; Zarife MAS; Schinoni MI; Paraná R; Dos Reis MG; Silva LK
Infect Drug Resist; 2017; 10():201-207. PubMed ID: 28740410
[TBL] [Abstract][Full Text] [Related]
6. Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection.
Sakurai F; Mitani S; Yamamoto T; Takayama K; Tachibana M; Watashi K; Wakita T; Iijima S; Tanaka Y; Mizuguchi H
Sci Rep; 2017 Apr; 7():45698. PubMed ID: 28374759
[TBL] [Abstract][Full Text] [Related]
7. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B.
Kim DY; Chang HY; Lim SM; Kim SU; Park JY; Kim JK; Lee KS; Han KH; Chon CY; Ahn SH
Gut Liver; 2013 May; 7(3):329-34. PubMed ID: 23710315
[TBL] [Abstract][Full Text] [Related]
8. Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.
Perales C; Beach NM; Gallego I; Soria ME; Quer J; Esteban JI; Rice C; Domingo E; Sheldon J
J Virol; 2013 Jul; 87(13):7593-607. PubMed ID: 23637397
[TBL] [Abstract][Full Text] [Related]
9. Viral quasispecies evolution.
Domingo E; Sheldon J; Perales C
Microbiol Mol Biol Rev; 2012 Jun; 76(2):159-216. PubMed ID: 22688811
[TBL] [Abstract][Full Text] [Related]
10. Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome.
Rodriguez-Frías F; Tabernero D; Quer J; Esteban JI; Ortega I; Domingo E; Cubero M; Camós S; Ferrer-Costa C; Sánchez A; Jardí R; Schaper M; Homs M; Garcia-Cehic D; Guardia J; Esteban R; Buti M
PLoS One; 2012; 7(5):e37874. PubMed ID: 22666402
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant hepatitis B virus strain in a chronic Turkish patient.
Sayan M; Hulagu S; Karatayli SC
Hepat Mon; 2010; 10(2):141-6. PubMed ID: 22312387
[TBL] [Abstract][Full Text] [Related]
12. Molecular diagnosis of entecavir resistance.
Sayan M
Hepat Mon; 2010; 10(1):42-7. PubMed ID: 22308125
[TBL] [Abstract][Full Text] [Related]
13. Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies.
Sayan M; Akhan SC; Senturk O
Hepat Mon; 2011 Oct; 11(10):835-42. PubMed ID: 22224083
[TBL] [Abstract][Full Text] [Related]
14. Current trends in management of hepatitis B virus reactivation in the biologic therapy era.
Mastroianni CM; Lichtner M; Citton R; Del Borgo C; Rago A; Martini H; Cimino G; Vullo V
World J Gastroenterol; 2011 Sep; 17(34):3881-7. PubMed ID: 22025876
[TBL] [Abstract][Full Text] [Related]
15. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.
Cuestas ML; Mathet VL; Oubiña JR; Sosnik A
Pharm Res; 2010 Jul; 27(7):1184-202. PubMed ID: 20333454
[TBL] [Abstract][Full Text] [Related]
16. Use of the novel INNO-LiPA line probe assay for detection of hepatitis B virus variants that confer resistance to entecavir therapy.
Jardi R; Rodriguez-Frias F; Tabernero D; Homs M; Schaper M; Esteban R; Buti M
J Clin Microbiol; 2009 Feb; 47(2):485-8. PubMed ID: 19052182
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
[TBL] [Abstract][Full Text] [Related]
18. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Zhang Y; He S; Li QL; Guo JJ
Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
